Caroline Loew - Mar 3, 2025 Form 4 Insider Report for Mural Oncology plc (MURA)

Role
Chief Executive Officer, Director
Signature
/s/ Maiken Keson-Brookes, attorney-in-fact for Caroline Loew
Stock symbol
MURA
Transactions as of
Mar 3, 2025
Transactions value $
-$14,492
Form type
4
Date filed
3/5/2025, 04:48 PM
Previous filing
Dec 18, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MURA Ordinary Shares Award $0 +72.3K +30.42% $0.00 310K Mar 3, 2025 Direct F1, F2
transaction MURA Ordinary Shares Sale -$14.5K -4.31K -1.39% $3.36 306K Mar 4, 2025 Direct F2, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MURA Stock Option (right to buy) Award $0 +134K $0.00 134K Mar 3, 2025 Ordinary Shares 134K $3.43 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Consists of ordinary shares issuable under 72,275 restricted stock units ("RSUs"). Each RSU represents the right to receive one ordinary share upon vesting. The RSUs are scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of March 3, 2025, subject to the reporting person's continued service with the Issuer.
F2 Includes 189,693 restricted stock units.
F3 Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on March 1, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement that includes a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on March 27, 2024, and the sale does not represent a discretionary trade by the Reporting Person.
F4 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.35 to $3.36. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 This option was granted on March 3, 2025. The option is scheduled to vest with respect to 25% of the underlying ordinary shares on March 3, 2026 and the remaining 75% of the underlying ordinary shares shall vest in 12 equal quarterly installments thereafter, subject to the reporting person's continued services with the Issuer.